Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
About Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc. (Nasdaq: COLL) is a leading specialty pharmaceutical company committed to improving the lives of patients living with chronic pain and other serious medical conditions. Headquartered in Stoughton, Massachusetts, the company leverages its proprietary DETERx® technology platform to develop and commercialize next-generation, abuse-deterrent medications. Collegium's innovative approach addresses the growing public health concerns surrounding the misuse and abuse of prescription drugs, particularly opioids, while maintaining efficacy for patients who require long-term pain management solutions.
Core Business and Product Portfolio
At the heart of Collegium’s operations is its portfolio of abuse-deterrent medications designed to mitigate risks associated with non-medical use. The company’s flagship product, Xtampza ER®, is an extended-release, oral formulation of oxycodone that employs DETERx® technology to maintain its safety and efficacy profile even when subjected to physical manipulation such as crushing or dissolving. Collegium also markets the Nucynta® franchise, which includes both immediate-release and extended-release formulations of tapentadol, used for managing acute and chronic pain.
In 2024, Collegium expanded its portfolio through the acquisition of Ironshore Therapeutics, adding Jornay PM®, a unique evening-dosed ADHD medication, to its offerings. This strategic move established the company’s presence in the growing neuropsychiatry market, diversifying its revenue streams and positioning it for long-term growth.
Technological Innovation: The DETERx® Platform
Collegium’s proprietary DETERx® technology is a cornerstone of its product development strategy. This platform enables the creation of extended-release formulations that are resistant to common forms of abuse, such as chewing, crushing, and dissolving. By integrating this technology into its medications, Collegium addresses two critical needs: providing effective pain relief for patients and reducing the potential for misuse and abuse. The DETERx® platform is protected by a robust portfolio of U.S. and international patents, underscoring Collegium’s commitment to innovation and intellectual property protection.
Strategic Growth and Market Position
Collegium has established itself as a key player in the specialty pharmaceutical industry through a combination of innovation, strategic acquisitions, and disciplined capital deployment. The company’s focus on responsible pain management has earned it a strong reputation among healthcare providers and patients alike. Its recent acquisition of Ironshore Therapeutics not only diversifies its product portfolio but also enhances its market presence in the neuropsychiatry segment.
With a strong financial foundation and a commitment to operational excellence, Collegium is well-positioned to navigate the challenges of a highly regulated industry. The company continues to invest in research and development, aiming to expand its portfolio and address unmet medical needs in both pain management and neuropsychiatry.
Commitment to Responsible Pain Management
Collegium is dedicated to advancing science-based solutions for pain management while prioritizing patient safety. The company actively engages with healthcare providers, policymakers, and the broader medical community to promote the responsible use of opioid medications. By combining innovative technology with a patient-centered approach, Collegium aims to set new standards in the treatment of chronic pain and other serious medical conditions.
Conclusion
Collegium Pharmaceutical Inc. exemplifies the integration of innovation, responsibility, and strategic growth in the pharmaceutical industry. Through its proprietary DETERx® technology, diverse product portfolio, and commitment to addressing critical public health challenges, the company continues to make meaningful contributions to the healthcare landscape. As it expands into new therapeutic areas like neuropsychiatry, Collegium remains focused on its mission to improve patient outcomes and create long-term value for stakeholders.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, set for April 13, 2022. Management will engage in a virtual fireside chat, which will be webcast and accessible through the investor section of the company's website. A replay will be available for 30 days following the event. Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts. For more details, visit www.collegiumpharma.com.
Collegium Pharmaceutical (Nasdaq: COLL) announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. McFarlane brings extensive experience from previous leadership roles at Adamas Pharmaceuticals and Retrophin. The Chairman, Mike Heffernan, expressed confidence in McFarlane's ability to provide valuable insights and contributions. This strategic addition comes as the company aims to enhance its operations and improve the lives of individuals with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has updated its financial guidance for 2022 following the acquisition of BioDelivery Sciences International on March 22, 2022. Expected total product revenues are projected between $450.0 million and $465.0 million, reflecting a 65% increase from $276.9 million in 2021. Adjusted operating expenses are estimated at $130.0 million to $140.0 million and adjusted EBITDA is expected to reach $235.0 million to $250.0 million. The company aims for operational synergies of at least $75 million as it integrates BDSI.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reached a Master Settlement Agreement to resolve 27 opioid-related lawsuits without admitting liability. Executed on March 18, 2022, the company has paid $2.75 million to the plaintiffs, leading to case dismissals anticipated in the upcoming weeks. This settlement follows a previously announced framework from December 2021, marking a strategic decision to mitigate legal risks. Collegium aims to strengthen its position as a specialty pharmaceutical company focused on aiding patients with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has completed its acquisition of BioDelivery Sciences International (Nasdaq: BDSI) for $5.60 per share, totaling approximately $40 million. This strategic move aims to enhance Collegium's revenue through diversification, adding products like BELBUCA and ELYXYB to its portfolio. The acquisition is expected to yield annual synergies of at least $75 million within the first year, strengthening Collegium's financial position and accelerating cash flow generation, while expanding its footprint in the neurology market.
Collegium Pharmaceutical (Nasdaq: COLL) reported its Q4 and full-year 2021 financial results, revealing a net loss of $25 million for Q4 and $71.5 million net income for the full year. The company anticipates 2022 revenues between $315 million and $330 million, driven by growth in Xtampza ER. They expect the BDSI acquisition to close in late Q1 2022, aiming for synergies exceeding $75 million. Despite challenges, Collegium ended 2021 with a cash balance of $186.4 million and achieved significant market share gains in Xtampza ER, with a 33% share of the oxycodone extended-release market.
Collegium Pharmaceutical (Nasdaq: COLL) announced an agreement to acquire BioDelivery Sciences International (BDSI) for $5.60 per share in cash, valuing BDSI at approximately $604 million. This acquisition, expected to close in Q1 2022, aims to enhance Collegium's portfolio in pain management and neurology, with estimated annual synergies of at least $75 million within 12 months. The transaction is anticipated to be accretive to earnings in 2022 and 2023, diversifying revenue sources and accelerating cash flow generation.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a conference call on February 24, 2022, at 4:30 p.m. ET to discuss its Q4 and full-year 2021 financial results. The call will be accessible via phone at (877) 407-8037 (U.S.) or (201) 689-8037 (International) and will also be available as a live audio webcast on their website. A replay will be posted approximately two hours after the event. Collegium is committed to advancing specialty pharmaceuticals aimed at improving patients' lives.
Collegium Pharmaceutical (Nasdaq: COLL) has reached a settlement framework to resolve 27 opioid-related lawsuits for a maximum payment of $2,750,000. This agreement aims to dismiss all pending cases while ensuring no admission of liability. The settlement, which awaits final approval, reflects the company's commitment to responsible pain management. Executive VP Shirley Kuhlmann expressed satisfaction with the resolution, indicating a focus on future operations free from this litigation burden.